Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.

ABSTRACT:

Importance

Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear.

Objective

To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US.

Design, setting, and participants

Descriptive study of reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS) that occurred after mRNA-based COVID-19 vaccine administration between December 2020 and August 2021 in 192 405 448 individuals older than 12 years of age in the US; data were processed by VAERS as of September 30, 2021.

Exposures

Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).

Main outcomes an

SUBMITTER: Oster ME 

PROVIDER: S-EPMC8790664 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature